Prognostic Capabilities of Diagnosing Non-Alcoholic Hepatic Steatosis at Early Stages of Its Development

The aim of the study is to substantiate the efficacy of new prognostic criteria in diagnosing non-alcoholic hepatic steatosis at early stages of its development.

Materials and Methods. Patients with excessive body mass (n=26) and obesity (n=28) having different concomitant pathologies of the digestive organs have undergone a comprehensive examination including assessment of biochemical blood indices, ultrasound examination of the abdominal organs, dynamic hepatobiliscintigraphy, assessment of the comorbidity level as a whole (calculation of CIRS) and by the available pathology of the digestive organs.

Results. The ultrasound signs of hepatic steatosis have been found in all patients with obesity stage II and III, in 69.2% of the examined patients (95% CI: 42.37–87.32) with obesity stage I, in 30.8% (95% CI: 16.50–49.99) with excessive body mass, and in 13.9% of patients (95% CI: 6.08–28.66) with normal body mass. According to the ROC analysis, the predictors of hepatic steatosis development in patients with excessive body mass and obesity are BMI (>31, р<0.0001) and the number of digestive organ illnesses (more than 4 diseases, p<0.0001). On the basis of the data obtained, a logistic model has been developed in the form of the regression equation permitting us to predict the groups of patients with a low or high degree of risk of hepatic steatosis. The analysis of dynamic hepatobiliscintigraphy has revealed deceleration of the absorbing function of hepatocytes in patients with normal ultrasound images of the liver even in case of excessive body mass. The obtained results made it possible to develop a method of diagnosing fatty hepatosis with subsequent calculation of the functional hepatocyte activity index (FHAI) which helps not only establish functional disorders but identify the group of patients having the risk of developing these disorders. Normal ultrasound imaging of the liver and absence of the biochemical changes in the blood are not indicators of preservation of its functional activity, since the risk of functional disorders was found in 32.3% of cases (95% CI: 18.57–49.86) and reversible disorders in 19.3% (95% CI: 9.19–36.28) when FHAI was calculated for patients with normal body mass. With the increase of body mass, irreversible functional disorders of hepatocytes are observed in 80–100% of patients.

Thus, the results obtained in the course of the investigation have confirmed the possibility of using new prognostic markers of hepatic steatosis for early diagnosis of non-alcoholic fatty liver disease.

1. Tishkovskiy S.V., Davydchyk E.V., Nikonova L.V. Non-alcoholic fatty liver disease and diabetes mellitus type 2 — the links of one process. Zurnal Grodnenskogo gosudarstvennogo medicinskogo universiteta 2016; 1: 92–98.
2. Statsenko M.E., Turkina S.V., Kosivtsova M.A., Shilina N.N. Non-invasive diagnosis of non-alcoholic fatty liver disease: simple “tools” are already in the hands of a practical doctor. Vestnik Volgogradskogo gosudarstvennogo medicinskogo universiteta 2019; 2: 134–139.
3. Lazebnik L.B., Golovanova E.V., Turkina S.V., Raikhelson K.L., Okovityy S.V., Drapkina O.M., Maev I.V., Martynov A.I., Roitberg G.E., Khlynova O.V., Abdulganieva D.I., Alekseenko S.A., Ardatskaya M.D., Bakulin I.G., Bakulina N.V., Bueverov A.O., Vinitskaya E.V., Volynets G.V., Eremina E.Yu., Grinevich V.B., Dolgushina A.I., Kazyulin A.N., Kashkina E.I., Kozlova I.V., Konev Yu.V., Korochanskaya N.V., Kravchuk Yu.A., Li E.D., Loranskaya I.D., Makhov V.M., Mekhtiev S.N., Novikova V.P., Ostroumova O.D., Pavlov C.S., Radchenko V.G., Samsonov A.A., Sarsenbaeva A.S., Sayfutdinov R.G., Seliverstov P.V., Sitkin S.I., Stefanyuk O.V., Tarasova L.V., Tkachenko E.I., Uspensky Yu.P., Fominykh Yu.A., Khavkin A.I., Tsyganova Yu.V., Sharhun O.O. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Eksperimental'naa i kliniceskaa gastroenterologia 2021; 1: 4–52, https://doi.org/10.31146/1682-8658-ecg-185-1-4-52.
4. Allakhverdieva Ya.S., Vorob’ev S.V., Mineev N.I. Modern opportunities of magnetic-resonance technologies in diagnostics of the fatty liver. Medicinskij vestnik Severnogo Kavkaza 2018; 13(4): 695–700, https://doi.org/10.14300/mnnc.2018.13140.
5. Akhmadullina G.I., Kurnikova I.A., Babin S.N., Evstyagina K.A. Diagnostic technique for fatty hepatosis. Patent RU 2578080. 2016.
6. Tsygankova O.V., Badin A.R., Starichkov A.A., Lozhkina N.G. Non-alcoholic fatty liver disease: a disease of civilization or a syndrome of modern age? Russkij medicinskij zurnal. Medicinskoe obozrenie 2018; 2(3): 23–28.
7. Maev I.V., Andreev D.N., Kucheryavyy Yu.A., Dicheva D.T., Kuznetsova E.I. Nealkogol’naya zhirovaya bolezn’ pecheni s pozitsiy sovremennoy meditsiny [Non-alcoholic fatty liver disease from the standpoint of modern medicine]. Moscow: Prima Print; 2020; 68 p.
8. Tsukanov V.V., Vasiutin A.V., Tonkikh Yu.L. Modern management of patients with nonalcoholic fatty liver disease. Doktor.Ru 2019; 3: 11–14, https://doi.org/10.31550/1727-2378-2019-158-3-11-14.
9. Trukhan D.I. Non-alcoholic fatty liver disease: current aspects of diagnosis in real clinical practice. Kliniceskij razbor v obsej medicine 2021; 2(4): 40–50, https://doi.org/10.47407/kr2021.2.4.00059.
10. Seliverstov P.V. Non-alcoholic fatty liver disease: from theory to practice. Arhiv vnutrennej mediciny 2015; 1: 19–26.
11. Krolevets T.S., Livzan M.A., Mozgovoy S.I. The role of the microbiome and intestinal mucosal barrier in the development and progression of non-alcoholic fatty liver disease. Rossijskij zurnal gastroenterologii, gepatologii, koloproktologii 2020; 30(5): 42–48, https://doi.org/10.22416/1382-4376-2020-30-5-42-48.

Akhmadullina G.I., Kurnikova I.А. Prognostic Capabilities of Diagnosing Non-Alcoholic Hepatic Steatosis at Early Stages of Its Development. Sovremennye tehnologii v medicine 2022; 14(4): 27, https://doi.org/10.17691/stm2022.14.4.03